Novartis得到Coartem Baby的许可,这是5公斤以下婴儿的首例疟疾治疗。 Novartis gets approval for Coartem® Baby, first malaria treatment for infants under 5 kg.

瑞士的Novartis制药公司已经获得Coartem baby的核准,这是对新生儿和5公斤以下婴儿的首例疟疾治疗。 Swiss pharmaceutical company Novartis has received approval for Coartem® Baby, the first malaria treatment for newborns and infants under 5 kg. 与疟疾新药研发公司和PAMA非洲联合体合作开发的这种破碎的樱桃植物药品解决了治疗患有疟疾的年轻婴儿方面的重大差距。 Developed in collaboration with Medicines for Malaria Venture and the PAMAfrica consortium, this dissolvable, cherry-flavored medicine addresses a critical gap in treating young infants with malaria. 治疗的目的是在疟疾流行地区增加获得治疗的机会,在这些地区,5岁以下儿童占全球疟疾死亡人数的大多数。 The treatment aims to enhance access in malaria-endemic regions, where children under 5 account for most malaria deaths globally.